The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback